CJC-1295

Research

CJC-1295 (with/without DAC)

Category
Growth Hormone
Aliases
DAC:GRF, Modified GRF 1-29
Administration
Subcutaneous injection

Documented benefits

Tier 1 · Peer-reviewed / regulatory

Benefit categories

Growth Hormone

CJC-1295's defining research application — a long-acting GHRH analog often paired with Ipamorelin for a stronger combined effect.

Anti-aging

Its influence on the growth hormone axis is studied for supporting markers associated with healthy aging.

Fat loss

Supports fat loss as a downstream effect of sustained growth hormone elevation over its multi-day active window.

Growth hormone stimulation

Binds GHRH receptors on pituitary somatotrophs, providing sustained stimulation rather than a single short pulse.

IGF-1 elevation

Its long half-life keeps IGF-1 elevated more continuously than shorter-acting growth hormone secretagogues.

Muscle growth

Supports lean muscle development through sustained IGF-1 elevation over its extended activity window.

Recovery improvement

Sustained growth hormone elevation is associated with steadier post-exercise recovery in user reports.